Monitor HUTCHMED's upcoming quarterly filings for any changes in revenue trends for ELUNATE, ORPATHYS and SULANDA following the expanded NRDL coverage. The renewal removes near-term reimbursement risk for these products.
Drugs in focus
HCM drug pipeline →ORPATHYS
◆ Mixed Named in this press release- Impact
- Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Next catalyst
- None dated
What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announced that three of its drugs (ELUNATE, ORPATHYS, SULANDA) will continue to be included in China's National Reimbursement Drug List (NRDL) effective January 1, 2027, with expanded coverage for new indications. This renewal supports ongoing commercial access and revenue from these products in China.
Key Facts
- ELUNATE (fruquintinib) newly included for renal cell carcinoma in combination with sintilimab
- ORPATHYS (savolitinib) newly included for EGFR-mutant NSCLC with MET amplification, in combination with osimertinib
- ORPATHYS renewed for NSCLC with MET exon 14 skipping alteration
- All previously included indications for ELUNATE, ORPATHYS and SULANDA maintained under multi-year agreements
- Updated NRDL effective January 1, 2027
Financial Impact
No financial figures provided; NRDL inclusion supports continued revenue from these drugs in China but pricing and volume impact not disclosed.
Risk Factors
- NRDL inclusion involves pricing negotiations that could pressure margins
- Competition from other targeted therapies in the same indications
- Reliance on China's annual NRDL renewal process for continued access
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3403144 |
Track record
33 reports on HCM
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 18 of 23 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Viewing Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers